A detailed history of Efg Asset Management (North America) Corp. transactions in Insmed Inc stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 50,867 shares of INSM stock, worth $3.58 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares
50,867
Previous 53,898 5.62%
Holding current value
$3.58 Million
Previous $3.61 Million 2.82%
% of portfolio
0.63%
Previous 0.64%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$62.0 - $79.01 $187,922 - $239,479
-3,031 Reduced 5.62%
50,867 $3.71 Million
Q2 2024

Jul 25, 2024

SELL
$22.0 - $69.71 $410,080 - $1.3 Million
-18,640 Reduced 25.7%
53,898 $3.61 Million
Q1 2024

May 13, 2024

BUY
$25.72 - $29.94 $329,576 - $383,651
12,814 Added 21.46%
72,538 $1.97 Million
Q4 2023

Feb 08, 2024

BUY
$23.42 - $31.74 $164,666 - $223,163
7,031 Added 13.34%
59,724 $1.85 Million
Q3 2023

Nov 02, 2023

SELL
$19.86 - $26.93 $99,915 - $135,484
-5,031 Reduced 8.72%
52,693 $1.33 Million
Q2 2023

Jul 28, 2023

SELL
$16.44 - $21.1 $56,159 - $72,077
-3,416 Reduced 5.59%
57,724 $1.22 Million
Q1 2023

Apr 27, 2023

SELL
$16.26 - $21.73 $55,657 - $74,381
-3,423 Reduced 5.3%
61,140 $1.04 Million
Q4 2022

Feb 03, 2023

BUY
$16.98 - $23.15 $277,062 - $377,738
16,317 Added 33.82%
64,563 $1.29 Million
Q3 2022

Oct 28, 2022

SELL
$20.88 - $28.21 $970,585 - $1.31 Million
-46,484 Reduced 49.07%
48,246 $1.04 Million
Q2 2022

Aug 04, 2022

SELL
$17.07 - $25.71 $138,744 - $208,970
-8,128 Reduced 7.9%
94,730 $1.87 Million
Q1 2022

Apr 26, 2022

SELL
$20.42 - $28.13 $18,745 - $25,823
-918 Reduced 0.88%
102,858 $2.42 Million
Q4 2021

Feb 18, 2022

BUY
$25.89 - $33.45 $2.69 Million - $3.47 Million
103,776 New
103,776 $2.83 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.54B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.